Dynamic monitoring of minimal residual disease in newly‐diagnosed multiple myeloma

作者：Pei‐Yu Yang, Weiling Xu, Xinyue Liang, Shanshan Yu, Xingcheng Yi, Mengmeng Liu, Mengru Tian, Tingting Yue, Yingjie Zhang, Yurong Yan, Zhongli Hu, Qiang Guo, Nan Zhang, Jingxuan Wang, Xiaoxiao Sun, Rui Hu, Shaji Kumar, Yun Dai, Fengyan Jin · 发表于：American Journal of Hematology · 年份：2022 · DOI：10.1002/ajh.26810 · 被引用次数：8 · 研究领域：Multiple Myeloma Research and Treatments、Protein Degradation and Inhibitors、Chemokine receptors and signaling

With the introduction of novel agents, more than 80% of patients with newly-diagnosed MM (NDMM) can achieve complete remission (CR) or better after first-line treatment.1 However, the majority of these patients eventually experience relapse, therefore calling for an additional approach to more precisely evaluate the depth of response and estimate the outcomes. Minimal residual disease (MRD) has been emerging as a reliable surrogate endpoint for progression-free survival (PFS) in clinical trials, while undetectable MRD strongly correlates with favorable outcomes, including both PFS and overall survival (OS).2 Over 50 ongoing phase III trials have included MRD as an endpoint to evaluate the depth of therapeutic response or assign MRD-directed treatment. Thus, MRD has been included into the revised International Myeloma Working Group (IMWG) criteria for assessment of therapeutic response.3 Moreover, the prognostic value of MRD seems independent of baseline risk factors such as advanced disease stage (e.g., ISS or R-ISS III) and high-risk cytogenetic abnormality (HRCA).4 However, several key issues remain to be addressed for incorporating the MRD test into daily practice.5 To this end, we conducted this retrospective study to explore the significance of dynamic monitoring of the MRD status in the management of NDMM patients. This study was approved by the Institutional Review Board (IRB) of the First Hospital of Jilin University (approval # 2018-087). The study included patients ...